{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytotoxic+drug", "query": { "intervention": "Cytotoxic drug" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 480, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytotoxic+drug&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T09:52:07.134Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02519322", "title": "Neoadjuvant and Adjuvant Checkpoint Blockade", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Mucosal Melanoma", "Ocular Melanoma", "Stage III Acral Lentiginous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Uveal Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IIIC Uveal Melanoma AJCC v7", "Stage IV Acral Lentiginous Melanoma AJCC v6 and v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2016-02-02", "completion_date": "2023-01-26", "has_results": true, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-09-20T09:52:07.134Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02519322" }, { "nct_id": "NCT05112601", "title": "Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Dedifferentiated Carcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Endometrioid Adenocarcinoma", "Recurrent Endometrial Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 81, "start_date": "2022-06-02", "completion_date": "2032-07-30", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-20T09:52:07.134Z", "location_count": 138, "location_summary": "Birmingham, Alabama • Athens, Georgia • Augusta, Georgia + 107 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Athens", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT05112601" }, { "nct_id": "NCT02724202", "title": "Curcumin in Combination With 5FU for Colon Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Metastatic Colon Cancer" ], "interventions": [ { "name": "Curcumin", "type": "DRUG" }, { "name": "5-flurorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-02-20", "completion_date": "2020-01-10", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-20T09:52:07.134Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02724202" }, { "nct_id": "NCT05014399", "title": "Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neoplasm, Colorectal", "Cognitive Impairment", "Cognitive Dysfunction", "Cognitive Change", "Chemo-brain", "Chemo Fog", "Chemotherapy Effect", "Cognitive Decline" ], "interventions": [], "intervention_types": [], "sponsor": "Joseph McCollom", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-09-20", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-20T09:52:07.134Z", "location_count": 1, "location_summary": "Fort Wayne, Indiana", "locations": [ { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014399" }, { "nct_id": "NCT00050063", "title": "Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Therapeutic vaccinations from A5058s", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": null, "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-20T09:52:07.134Z", "location_count": 14, "location_summary": "Torrance, California • Aurora, Colorado • Indianapolis, Indiana + 5 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00050063" }, { "nct_id": "NCT02482532", "title": "Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "tvs-CTL Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gary Doolittle", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 7, "start_date": "2016-10-06", "completion_date": "2021-09-13", "has_results": false, "last_update_posted_date": "2022-02-04", "last_synced_at": "2026-09-20T09:52:07.134Z", "location_count": 1, "location_summary": "Fairway, Kansas", "locations": [ { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02482532" }, { "nct_id": "NCT00000904", "title": "Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" }, { "name": "gp160 MN/LAI-2", "type": "BIOLOGICAL" }, { "name": "ALVAC(1)120(B,MN)GNP (vCP1433)", "type": "BIOLOGICAL" }, { "name": "ALVAC-HIV MN120TMG (vCP205)", "type": "BIOLOGICAL" }, { "name": "ALVAC-RG Rabies Glycoprotein (vCP65)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 100, "start_date": null, "completion_date": "1999-08", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-20T09:52:07.134Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000904" }, { "nct_id": "NCT04072393", "title": "Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer", "Esophageal Cancer", "Thoracic Cancer", "Hodgkin Lymphoma", "Hodgkin Disease", "Non-hodgkin Lymphoma", "Sarcoma", "Thymoma", "Breast Cancer" ], "interventions": [ { "name": "Home-based cardiac rehabilitation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2021-01-15", "completion_date": "2024-05-15", "has_results": false, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-09-20T09:52:07.134Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072393" }, { "nct_id": "NCT01950390", "title": "Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2014-01-24", "completion_date": "2025-01-31", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-09-20T09:52:07.134Z", "location_count": 482, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 298 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01950390" }, { "nct_id": "NCT00104468", "title": "Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "Troxatyl™ (Cytotoxic Chemotherapeutic)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SGX Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2003-04", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2008-01-17", "last_synced_at": "2026-09-20T09:52:07.134Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104468" } ] }